Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models

SHIGETO KAWAI1*, YASUSHI YOSHIMURA1†, SHIN-ICHIRO IIDA1, YASUKO KINOSHITA1, YASUO KOISHIHARA1, SHUJI OZAKI2, TOSHIO MATSUMOTO2, MASAAKI KOSAKA3 and HISAFUMI YAMADA-OKABE1

1Pharmaceutical Research Department III, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530; 2Department of Medicine and Bioregulatory Sciences, Institute of Health Biosciences, The University of Tokushima Graduate School and Division of Transfusion Medicine, Tokushima University Hospital, Tokushima 770-8501; 3Tokushima Red Cross Blood Center, Tokushima 770-0044, Japan

Received August 17, 2005; Accepted October 5, 2005

Abstract. A humanized monoclonal antibody against HM1.24 antigen (AHM), which is highly expressed on multiple myeloma (MM) cells, induced antibody-dependent cellular cytotoxicity (ADCC) in vitro. In this study, we further characterized AHM and evaluated its potency for clinical application. AHM bound to HM1.24 antigen with a dissociation constant of 0.35 nM, and its epitope resided between Leu116 and Leu127 of the HM1.24 antigen. Single intravenous injection of AHM significantly inhibited tumor growth in both orthotopic and ectopic human MM xenograft models. AHM reduced serum M protein levels and prolonged survival of mice intravenously inoculated with KPMM2 and ARH-77 cells. The number of KPMM2 cells in bone marrow or tumor volume of subcutaneously inoculated RPMI 8226 cells was also inhibited by AHM. The antitumor activity of AHM against tumor cells in bone marrow was diminished when the mice were pretreated with anti-Fcγ receptor III/II antibody, demonstrating that antitumor activity by AHM requires effector cell functions in vivo. Experiments involving in vitro ADCC assays indicated that NK cells and monocytes/macrophages serve as effector cells for AHM-induced ADCC in mouse and human. Thus, AHM will provide an additional treatment option for MM.

Introduction

Patients with multiple myeloma (MM), caused by clonal expansion of plasma cells and subsequent invasion of the tumor cells into bone marrow, suffer from severe anemia, humoral immunodeficiency and concomitant microbial infections (1). In addition, MM patients often show elevated blood levels of interleukin-6 (IL-6), IL-1ß and tumor necrosis factor α. Because these cytokines enhance osteolysis, patients suffer from bone pain, fractures and hypercalcemia (2). Recently, new therapies such as thalidomide and Velcade have been used in clinic and have shown improved antitumor effect against MM. However, efficacy of these drugs is still not satisfactory, and they can cause adverse effects such as peripheral neuropathy, which limits the full-dose combination with other chemotherapeutic agents (3-5). Therefore, development of potent and safe new drugs is required.

Previously, we generated a monoclonal antibody (mAb) against the HM1.24 antigen (also named CD317) that is highly expressed in terminally differentiated normal and neoplastic B cells (6,7). The mouse mAb against HM1.24 (mAHM) was effective in human MM xenograft models (8). In addition, we created a humanized anti-HM1.24 mAb (AHM) and found that it induced antibody-dependent cellular cytotoxicity (ADCC) against human MM cell lines (9). Although AHM induced complement-dependent cytotoxicity (CDC) in the presence of baby rabbit complements, no CDC occurred in the presence of human or mouse serum (10). Therefore, AHM is considered to elicit antitumor activity through ADCC both in mouse and human.

In this study, we further characterized AHM and evaluated its potency for clinical applications. AHM bound to HM1.24 antigen with a similar dissociation constant (Kd) to that of mAHM, and showed significant tumor growth inhibition and prolonged survival in human MM xenograft models in a manner dependent on effector cell functions. Furthermore, NK cells and monocytes/macrophages are expected to serve as effector cells both in mouse and human.

Materials and methods

Antibodies. A mouse mAb carrying mouse IgG2ax (mAHM) and a humanized mAb carrying the human IgG1x (AHM) against the HM1.24 antigen were prepared as reported...
Cells (10^6 cells/ml) were incubated with antibody binding assay. Cells were then washed twice with phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) and cultured in RPMI-1640 medium supplemented with 20% fetal bovine serum (FBS). For Flow cytometry, cell surface expression of the HM1.24 antigen was analyzed by flow cytometry. Cells (5x10^5) were incubated with 40 μg/ml mAHM-FITC or mIgG2a-FITC in phosphate buffered saline (PBS) containing 0.1% bovine serum albumin and 0.1% sodium azide (FCM/PBS) for 30 min on ice. Cells were then washed twice with FCM/PBS and analyzed using an EPICS XL flow cytometer (Beckman Coulter, Tokyo, Japan).

Flow cytometry. Cell surface expression of the HM1.24 antigen was analyzed by flow cytometry. Cells (5x10^5) were incubated with 40 μg/ml mAHM-FITC or mIgG2a-FITC in phosphate buffered saline (PBS) containing 0.1% bovine serum albumin and 0.1% sodium azide (FCM/PBS) for 30 min on ice. Cells were then washed twice with FCM/PBS and analyzed using an EPICS XL flow cytometer (Beckman Coulter, Tokyo, Japan).

Antibody binding assay. Cells (10^6 cells/ml) were incubated with 0.125 nM ^125I-AHM and serial dilutions of non-radio labeled AHM for 3 h on ice. Then, the cells were gently applied onto FBS, separated from the supernatants by centrifugation at 11,000 x g for 3 min, and frozen at -80°C. The resulting frozen cell pellets and supernatants were isolated by cutting the sample tubes and radioactivity was quantified by a COBRA meter (Beckman-Dickinson). To examine the involvement of Fcγ receptors (FcγRs) in antitumor activity of AHM, mice were administered 250 μg/mouse of anti-mouse FcγRIII/II mAb (BD Pharmingen, Franklin Lakes, NJ) or control PE-labeled mouse IgG1 (Becton-Dickinson) on ice for 30 min. CD38 positive tumor cells in the bone marrow were analyzed by FACScan flow cytometer (Becton-Dickinson). To examine the involvement of FcγR receptors (FcγRs) in antitumor activity of AHM, mice were administered 250 μg/mouse of anti-mouse FcγRIII/II mAb (BD Pharmingen, Franklin Lakes, NJ) or control PE-labeled mouse IgG1 (Becton-Dickinson) on ice for 30 min. CD38 positive tumor cells in the bone marrow were analyzed by FACScan flow cytometer (Becton-Dickinson). To examine the involvement of Fcγ receptors (FcγRs) in antitumor activity of AHM, mice were administered 250 μg/mouse of anti-mouse FcγRIII/II mAb (BD Pharmingen, Franklin Lakes, NJ) or control PE-labeled mouse IgG1 (Becton-Dickinson) on ice for 30 min. CD38 positive tumor cells in the bone marrow were analyzed by FACScan flow cytometer (Becton-Dickinson). To examine the involvement of Fcγ receptors (FcγRs) in antitumor activity of AHM, mice were administered 250 μg/mouse of anti-mouse FcγRIII/II mAb (BD Pharmingen, Franklin Lakes, NJ) or control PE-labeled mouse IgG1 (Becton-Dickinson) on ice for 30 min. CD38 positive tumor cells in the bone marrow were analyzed by FACScan flow cytometer (Becton-Dickinson).
Preparation of effector cells. Peripheral blood was obtained from healthy volunteers after approval by the Ethics Committee of Chugai Pharmaceutical Co., Ltd. Peripheral blood mononuclear cells (PBMCs) were separated by gradient centrifugation with Ficoll-Paque (Amersham Bioscience). NK cells were depleted from PBMCs by magnetic cell sorting with CD56 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany). NK cells and monocytes were purified from PBMCs by magnetic cell sorting with NK Cell Isolation Kit and Monocyte Isolation Kit (Miltenyi Biotec), respectively.

Spleen cells were obtained from SCID mice. NK cells were depleted by administration of rabbit anti-asialo GM1 antiserum 1 day before harvesting effector cells in some of the mice and macrophages were obtained by rinsing the peritoneal cavity of these mice. Purified macrophages were positive for F4/80 (macrophage marker) but negative for DX5 (pan-NK cell marker) or Gr-1 (neutrophil marker) and did not show natural killer activity against NK-sensitive YAC-1 cells. The mAbs for the flow cytometry were purchased from BD Pharmingen except for F4/80 (Cederlane, Ontario, Canada).

Determination of ADCC activities. ADCC activity of AHM was determined by 51Cr release assay. Target cells were labeled with 150 μCi (5.55 MBq) of 51Cr-sodium chromate (Amersham Pharmacia) at 37°C for 1 h. The cells were then washed three times with RPMI-1640 medium supplemented with 10% FBS and suspended in the same medium. The radiolabeled cells were plated on 96-well round-bottomed plates (10^4 cells/well) and incubated with various concentrations of AHM or hIgG1 on ice for 15 min. In some experiments, anti-human FcγRIII F(ab')2 mAb (Medarex, Ammandale, NJ), anti-human FcγRII Fab mAb (Medarex), anti-human FcγRI F(ab')2 mAb (Anceil, Bayport, MN), or anti-mouse FcγRIII/II mAb were added to the culture at a concentration of 10 or 20 μg/ml. Effector cells were then added to the cells at various effector-to-target (E:T) ratios, and the cells were further incubated for 4 or 8 h. One hundred microliters of the supernatant from each well was collected and radioactivity in the supernatants was measured using a gamma counter. Radioactivity in the supernatants of the 51Cr-labeled cells incubated without effector cells and antibodies was considered spontaneous 51Cr release; those of the cells after incubation in 1% NP-40 solution were considered maximum 51Cr release. Cytotoxicity (%) was determined with the formula: (A-C)/(B-C) x 100 where A, B and C represent 51Cr release in each experiment, maximum 51Cr release, and spontaneous 51Cr release, respectively. All experiments were done in triplicate and values in the figures are means ± SD.

Statistical analysis. Survival of the mice, M protein, and tumor weight were analyzed by Dunnett's test, and differences with P-values of <0.05 were considered significant.

Results and Discussion

Antigen binding and epitope of AHM. First, we determined the affinity of AHM to HM1.24 antigen by flow cytometry and 125I-AHM binding assay (Fig. 1). The Kd of AHM to the antigen was 0.346±0.055 nM (mean ± SD, n=6), which was very similar to that of mAHM (1.09 nM) (7). AHM was reported to bind cell surface HM1.24 antigen and kill target cells by ADCC (9), but the epitope of AHM remains to be clarified. Therefore, we mapped the epitope of AHM by Western blotting using GST fusion protein carrying various parts of HM1.24 antigen. AHM bound to C-terminally deleted HM127 encompassing Val1-Leu127 but not to HM126 encompassing Val1-Lys126, indicating that the epitope is
present between Val35 and Leu127 (Fig. 2A). On the other hand, AHM bound to N-terminally deleted HM116C encompassing Leu116-Gln180 but not to HM117C encompassing Glu117-Gln180, indicating that the epitope locates between Leu 116 and Gln180 (Fig. 2B). Therefore, the epitope of AHM resides between Leu116 and Leu127 of the HM1.24 antigen (Fig. 2C).

Antitumor activity of AHM in mouse xenograft models. As mentioned above, AHM killed HM1.24 antigen-positive human MM cells through ADCC in the presence of human effector cells (9). Therefore, we evaluated the antitumor activities of AHM in orthotopic and ectopic tumor xenograft models using KPMM2, RPMI 8226 and ARH-77 cells. Amounts of HM1.24 antigen on KPMM2, RPMI 8226 and ARH-77 cells were estimated by Scatchard analysis as 5.97x10^4, 8.72x10^4 and 8.47x10^4 molecules/cell, respectively. Mice intravenously injected with KPMM2 showed tumor masses in bone marrow, osteolytic lesions, hypercalcemia and increased serum M protein (13), and all mice died before day 44 (Fig. 3A).
Administration of AHM (4 or 20 μg/mouse) on day 10 markedly decreased serum M protein levels and prolonged the survival of the mice as compared to those receiving the control antibody. In addition, the antitumor activity of AHM as revealed by serum M protein and survival was almost equivalent to that of 3 mg/kg melphalan (Fig. 3A and B). In KPMM2-bearing mice, plasma half-life and serum concentration of AHM 21-28 days after administration of 20 μg/mouse AHM were about 8 days and approximately 1 μg/ml, respectively (Fig. 3C). Because 1 μg/ml of AHM was sufficient for the maximum ADCC against KPMM2 cells in vitro, doses should be set to maintain 1 μg/ml or higher concentrations of AHM in serum.

We also examined whether AHM impaired the growth of tumor cells in bone marrow. Administration of AHM (1 mg/kg) on day 12 suppressed the growth of KPMM2 cells in the bone marrow (Fig. 4A), which was diminished by administration of anti-mouse FcRIII/II mAb (Fig. 4B). The results indicate AHM affects the growth of tumor cells in bone marrow and that the effect is mediated by effector cell functions.

Antitumor activity of AHM was also examined in two other xenograft models. Mice intravenously inoculated with ARH-77 developed tumors not only in bone marrow but also in lymph nodes, especially around the neck, adrenal gland or intestine, thereby representing highly metastatic states of cancer. Even in such xenograft model, single administration of 20 or 100 μg/mouse AHM on day 10 suppressed the serum M protein levels and prolonged the survival as compared to the mice receiving the control antibody (Fig. 5). Tumor growth inhibition by AHM was also evident in the ectopic model. Administration of 0.25 or 1 mg/kg AHM on day 17 to mice subcutaneously inoculated with RPMI 8226 significantly inhibited tumor growth as evidenced by tumor volume and tumor weight (Fig. 6).

**Effector cells for the ADCC activity of AHM.** Since antitumor effects by AHM are mediated by effector cell functions (9),...
we asked which effector cells are responsible for the anti-tumor activity of AHM. As shown in Fig. 7A, AHM induced ADCC against ARH-77, and to a much lesser extent against KPMM2, with murine spleen cells. ADCC activity was completely diminished in spleen cells collected from mice in which NK cells were depleted. Strong ADCC activity against ARH-77 and KPMM2 was observed with macrophages isolated from the peritoneal cavity of mouse, and the ADCC was nearly completely inhibited by anti-mouse Fc\(\gamma\)RIII/II mAb (Fig. 7B). The results indicate that in mouse, macrophages and NK cells mediate the ADCC activity of AHM.

We also asked which types of effector cells mediate the antitumor activity of AHM in human. AHM induced ADCC against KPMM2, with murine spleen cells. ADCC activity was completely diminished in spleen cells collected from mice in which NK cells were depleted. Strong ADCC activity against ARH-77 and KPMM2 was observed with macrophages isolated from the peritoneal cavity of mouse, and the ADCC was nearly completely inhibited by anti-mouse Fc\(\gamma\)RIII/II mAb (Fig. 7B). The results indicate that in mouse, macrophages and NK cells mediate the ADCC activity of AHM.

Recently, thalidomide and Velcade have been shown to be effective in the treatment of MM in clinic (3-5). Nevertheless, efficacy of these drugs is still not satisfactory, and these drugs cannot be easily combined with other drugs due to their toxicity. In a phase I/II study, AHM did not cause any serious toxicity when administered to patients with relapsed or refractory MM (Powles R, et al, Japanese Multiple Myeloma

Figure 6. Antitumor activity of AHM in RPMI 8226 xenograft model. SCID mice were subcutaneously inoculated with 6x10^6 cells/mouse of RPMI 8226 cells. Then, they were intravenously administered 0.25 or 1 mg/kg of AHM or PBS on day 17. Tumor volume was measured once a week (A), and tumor weight was measured on day 45 (B). Each group consisted of 10 mice. Asterisks indicate significant difference between the test group and the control group (p<0.05 by Dunnett’s test). Day 0 represents the day when the mice were inoculated with tumors. □, AHM (1 mg/kg); △, AHM (0.25 mg/kg); ◇, PBS.

Figure 7. ADCC activity of AHM mediated by murine effector cells. (A), Spleen cells were collected from SCID mice. To deplete NK cells, mice were administered rabbit anti-asialo GM1 antiserum 1 day before harvesting spleen cells. KPMM2 or ARH-77 cells that had been labeled with ^51Cr were incubated with splen cells containing (+NK) or not containing (-NK) NK cells for 4 h at an E:T ratio of 60 in the presence of 1 \(\mu\)g/ml AHM (white) or hIgG1 (grey). (B), Macrophage was collected from peritoneal cavity of SCID mice that had been administered rabbit anti-asialo GM1 antiserum 1 day before harvest. KPMM2 and ARH-77 cells that had been labeled with ^51Cr were incubated with macrophages for 8 h at an E:T ratio of 50 in the presence of 1 \(\mu\)g/ml AHM (white) or IgG1 (grey) together with or without 20 \(\mu\)g/ml α-Fc\(\gamma\)RIII/II mAb (hatched).
Therefore, AHM may be safely combined with other drugs at full dose in clinical settings to further improve the efficacy.

Acknowledgements

We thank F. Ford for proofreading the manuscript.

References


Figure 8. ADCC activity of AHM mediated by human effector cells. (A), PBMC was collected from peripheral blood of healthy volunteers. NK cells were depleted from PBMC by magnetic cell sorting. KPM2M cells that had been labeled with 51Cr were incubated with PBMC containing (+NK) or not containing (-NK) NK cells for 4 h at an E:T ratio of 20 in the presence of 1 μg/ml AHM (white) or hlgG1 (grey). (B), NK cells were purified by magnetic cell sorting from PBMC collected from healthy volunteers. ADCC activity of AHM against KPM2M cells was determined as in (A). Anti-FcγRIII, II or I mAbs were added to the culture to give a final concentration of 10 μg/ml AHM (white) or hlgG1 (grey). (C), Monocytes were purified by magnetic cell sorting from PBMC collected from healthy volunteers. ADCC activity of AHM against KPM2M cells was determined as in (A) except for an E:T ratio of 50. Anti-FcγRIII, II or I mAbs were added to the culture to give a final concentration of 10 μg/ml AHM.